Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
BiBBInstruments AB ("BiBB" or the "Company"), a cancer diagnostics company developing EndoDrill® - the world's first market-cleared powered biopsy instrument for endoscopy - today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for one of its core EndoDrill® patents. This indicates that the USPTO intends to grant a patent for EndoDrill® within Patent Family 1 in the United States. Following certain formal steps, the final patent will be granted, providing protection for the technology until 2039.
BiBB has received a Notice of Allowance for U.S. patent application 17/283,928, part of its Patent Family 1. This patent provides broad protection for the EndoDrill® product series in the U.S. market. The Company currently has three international patent applications for EndoDrill® that have entered the national/regional phase, with patents already granted in the U.S., Europe, Japan, India, and China. The remaining patent applications will continue to be pursued to secure global protection for the world's first powered endoscopic biopsy instrument.
"The approval of our first U.S. patent is a very important milestone for BiBB as we move towards commercialization in the United States. This is a well-timed development, as we recently signed a Letter of Intent (LOI) with TaeWoong Medical USA for the distribution of our flagship product, EndoDrill® GI," says Fredrik Lindblad, CEO of BiBB.
This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.
For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com
This disclosure contains information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:30 CET on May 15, 2025.
About BiBB
The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill® GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. Thus EndoDrill® is the first cleared powered endoscopic biopsy system in both the US and Europe. The EndoDrill® system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.